Anti-tumor effect of boron neutron capture therapy in pelvic human colorectal cancer in a mouse model

Biomed Pharmacother. 2022 Oct:154:113632. doi: 10.1016/j.biopha.2022.113632. Epub 2022 Sep 2.

Abstract

Local recurrence of colorectal cancer (CRC) can occur in patients after curative resection, and additional surgical resection may therefore be required; however, this is a significant burden for patients, because additional surgical resection may necessitate the resection of other organs such as the bladder, prostate, uterus, or sacral bone. Therefore, there is a need for alternative therapeutic strategies. We focused on boron neutron capture therapy (BNCT) as a treatment modality that can selectively target tumor cells without excessive damage to normal tissues. The usefulness of BNCT to pelvic CRC remains unknown. This study investigated the anti-cancer effect of boronophenylalanine (BPA)-mediated BNCT in a previously established mouse model of pelvic recurrence of CRC. Uptake of BPA in CRC was observed both in vitro and in vivo, and the concentrations were sufficient for BNCT. Our results are the first to show that BPA-mediated BNCT prolonged the survival of experimental mice with pelvic tumors; moreover, it did not cause any obvious severe side effects in the treated animals. In conclusion, BPA-mediated BNCT could contribute to treating local recurrence of pelvic CRC.

Keywords: Boron neutron capture therapy; Boronophenylalanine; Colorectal cancer; Pelvic recurrence.

MeSH terms

  • Animals
  • Boron Compounds / therapeutic use
  • Boron Neutron Capture Therapy* / adverse effects
  • Boron Neutron Capture Therapy* / methods
  • Colorectal Neoplasms* / drug therapy
  • Disease Models, Animal
  • Female
  • Humans
  • Male
  • Mice
  • Mouth Neoplasms* / pathology
  • Pelvic Neoplasms* / drug therapy
  • Pelvic Neoplasms* / etiology

Substances

  • Boron Compounds